COVID-19 Peer-Reviewed Medical Research Programs

The U.S. Army Medical Research Acquisition Activity (USAMRAA) is accepting applications related to COVID-19 research to the 2020 Peer Reviewed Medical Research Program (PRMRP) under the Congressionally Directed Medical Research Programs (CDMRP). The 2020 budget for PRMRP is $360 million. The proposed research must be relevant to active duty service members, veterans, military beneficiaries, and/or the American public.



Clinical Trial Award

Letter of Intent: June 8, 2020

Application Deadline: June 22, 2020

Budget: ~$5M



Investigator-Initiated Research Award

Letter of Intent: May 28, 2020

Application Deadline: June 12, 2020

Budget: up to $1.6M / $2M with partnering PI



Technology / Therapeutic Development Award

Letter of Intent: May 28, 2020

Application Deadline: June 12, 2020

Budget: up to $4M





All applications for the Program Announcements must specifically address at least one of the following Focus Areas and must be of clear scientific merit and direct relevance to military health. APPLICATIONS WILL NOT BE REVIEWED IF THEY ARE OUTSIDE THE SCOPE


Emerging Viral Diseases

  1. On demand identification, isolation, characterization and manufacturing of antibodies from patients with COVID-19.
  2. Development of a wearable sensor providing real-time diagnostics to be used as a point of care for emerging viral diseases to predict illness before onset of symptoms. The diagnostic platform should be applicable to COVID-19. Virus-specific markers that can identify viruses at the genus level can be included.
  3. Surveillance and predictive modeling tools that leverage AI to predict outbreaks and epidemics and support strategies for mitigating the threat of COVID-19.
  4. Triage of care for COVID-19 patients requiring access to resource-intensive interventions.
  5. Research to understand novel molecular and biological mechanisms of COVID-19 health impacts and identification/validation of biochemical, physiological, or combined biomarkers for evaluating short- and long-term health impacts from COVID-19.
  6. Research to determine direct and indirect impacts of COVID-19 on military readiness and unit climate; interpersonal/family dynamics; behavioral and mental health issues to inform, develop, and test potential behavioral countermeasures.


Respiratory Health

  1. Etiology and prevention of ARDS caused by responses to coronaviruses, particularly COVID-19.
  2. Development of improved methods for assessing and treating lung injury due to coronaviruses, particularly COVID-19.
  3. Novel and/or innovative detection technologies or therapeutics to reduce incidence and/or severity of ARDS and/or other lung injury secondary to coronaviruses, particularly COVID19.
  4. Development of biomarker metrics to associate the long-term health outcomes of virus induced ARDS with degradation of physiological and physical performance.
  5. Ventilation and Extracorporeal Life Support technologies to support lung function or airway management that increase survivability and/or minimize provider burden or exposure.
  6. Pharmacological and biologic interventions for COVID-19 induced complications.
  7. Research on the short- and long-term health impacts of COVID-19 diagnosed Service members on readiness, deployability, and fitness for duty
  8. Prevention of COVID-19 (and other respiratory pathogens) in aircraft, ships, and submarines



There are three mechanisms through which an application for funding for relevant COVID-19 research can be awarded with different due dates (see above). There is no grace period on these dates.


The Clinical Trial Award supports clinical trials with potential for significant impact in one or more Focus Areas. They may be designed to evaluate new products, pharmacologics, devices, clinical guidance, and/or emerging approaches and technologies. Projects may range from small proof-of-concept trials through large-scale trials. A clinical trial is defined as a study in which one or more human subjects are prospectively assigned to one or more interventions to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.


The Investigator-Initiated Research Award is intended to support studies that will make an important contribution toward research and/or patient care in one or more Focus Areas.


The Technology/Therapeutic Development Award is a product-driven award mechanism providing support for the translation of promising preclinical findings into products for clinical applications in one or more Focus Areas. Products in development should be responsive to the healthcare needs of military Service members, Veterans, and/or beneficiaries.